GlobeNewswire Inc.··NaLiminatus Pharma Faces Nasdaq Delisting After Failing Market Value Tests
Liminatus Pharma received Nasdaq delisting notice after failing market value requirements. Company plans May 27 appeal to Nasdaq Hearings Panel.
LIMNLIMNWbiopharmaceuticalNasdaq